CSBio CSBio

X
[{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$200.0 million","newsHeadline":"PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Megapharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PharmaMar and Megapharm sign a licensing agreement for lurbinectedin in Israel","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca\u00ae (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"Inbiomotion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Shows That Selection of Breast Cancer Patients for Adjuvant Bisphosphonate Therapy Based on Inbiomotion's MAFTEST\u00ae Reduces the Risk of Death in Comparison With Current Clinical Guidance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Inbiomotion"}]

Find Oncology Drugs in Phase III Clinical Development in SPAIN

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            MAFTEST® adjuvant bisphosphonates therapy Bonefos, (clodronate disodium) result showed significant efficacy and reduce risk of death at 5 and 10 years by 26% and 23% respectively in early-stage (stage I-III) breast cancer patients compared with current clinical guidelines.

            Lead Product(s): Clodronic Acid Disodium Salt

            Therapeutic Area: Oncology Product Name: Bonefos

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Zepzelca (lurbinectedin) is a DNA-negative allosteric modulator. It is being developed for the treatment of patients with relapsed small cell lung cancer.

            Lead Product(s): Lurbinectedin,Irinotecan Hydrochloride

            Therapeutic Area: Oncology Product Name: Zepzelca

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This new agreement will allow lurbinectedin to reach the Israeli market, if approved, in the hands of one of the leading companies in the field of oncology in this country.

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Megapharm

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PharmaMar & Jazz signed an exclusive license agreement for U.S. rights to lurbinectedin, the effectiveness of which was subject to the expiration or early termination of the applicable HSR waiting period.

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jazz Pharmaceuticals

            Deal Size: $1,000.0 million Upfront Cash: $200.0 million

            Deal Type: Licensing Agreement January 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY